Myriad Genetics
MYGN
191 hedge funds and large institutions have $1.55B invested in Myriad Genetics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 73 increasing their positions, 59 reducing their positions, and 26 closing their positions.
254% more call options, than puts
Call options by funds: $2.97M | Put options by funds: $839K
24% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 59
7% more capital invested
Capital invested by funds: $1.45B → $1.55B (+$101M)
1.63% more ownership
Funds ownership: 99.43% → 101.06% (+1.6%)
4% less funds holding
Funds holding: 198 → 191 (-7)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$29.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$11M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$10.3M |
| 4 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$8.67M |
| 5 |
Goldman Sachs
New York
|
+$7.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$9.98M |
| 2 |
D.E. Shaw & Co
New York
|
-$6.53M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$5.4M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.1M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$4.7M |
MYGN Hedge Fund Activity: Q3 2022 in Review
191 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2022, worth a combined $1.55B — up 6.9% from $1.45B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MYGN and 19 opened new positions — a net loss of 7 holders — while 59 trimmed existing stakes and 73 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $29.1M. The largest seller was PFM Health Sciences, cutting an estimated $9.98M.
- 191 institutional investors held Myriad Genetics (MYGN) as of Q3 2022, down from 198 in Q2 2022.
- Funds reported $1.55B of Myriad Genetics stock for Q3 2022, up 6.9% quarter-over-quarter.
- 19 funds opened new Myriad Genetics positions in Q3 2022 and 26 closed out, a net change of -7 holders.
- The largest Myriad Genetics buyer in Q3 2022 was Millennium Management, an estimated $29.1M added.
- The largest Myriad Genetics seller in Q3 2022 was PFM Health Sciences, an estimated $9.98M sold.
Based on aggregated 13F filings for Q3 2022.